Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 484 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; Sterile Saline Clear all
Completed Phase 1 Interventional

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783
View directory record Official record
Conditions
Influenza A
Interventions
VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
51
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin to Treat COVID-19 Long Haulers

NCT05228899
View directory record Official record
Conditions
COVID-19
Interventions
Zofin, Placebo
Drug · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Newport Beach, California • North Hollywood, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

NCT02724085
View directory record Official record
Conditions
Pneumonia
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

NCT01518985
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bendavia, Sterile saline (0.9%), Cigarette smoking
Drug · Other
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety and PK Study of IV TP-271

NCT03234738
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 4 Interventional Results available

Vital Capacity in Ultrasound Guided Serratus Plane Block in ED Patients With Multiple Rib Fractures

NCT04530149
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen, Bupivacain, Saline
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107
View directory record Official record
Conditions
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions
Xembify, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Not listed Phase 1 Interventional

Assessing Ketorolac (Toradol) at Oocyte Retrieval

NCT06026553
View directory record Official record
Conditions
Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
Interventions
Ketorolac (Toradol), Placebo (saline)
Drug · Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 14, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

NCT06665100
View directory record Official record
Conditions
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PUL-042, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Inflammation and Threat Sensitivity in PTSD

NCT03048929
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

NCT04331002
View directory record Official record
Conditions
Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions
Zilretta, Placebo
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept (POC) in Patients With Ischaemic Stroke

NCT01808261
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320 100/mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 14, 2026, 10:45 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 10:45 PM EDT